Context: Radioactive iodine (RAI) has been epidemiologically associated with the development of hematologic malignancies. Clonal hematopoiesis (CH) is a precursor clonal state that confers increased risk of leukemia and occurs at an elevated rate in patients with thyroid cancer relative to other solid tumors.
R adioactive iodine (RAI) administration, following total thyroidectomy, has been traditionally used as an adjuvant treatment of all stages of well-differentiated thyroid carcinoma. More recently, the benefits of such therapy have been questioned in low-and intermediaterisk patients with thyroid cancer, given reports of marginal or no improvement of recurrence or mortality rates in this setting (1) (2) (3) . Based on these reports and others (4, 5) , the American Thyroid Association and the National Comprehensive Cancer Network guidelines recommend a tailored administration of RAI based on a risk-adapted approach, where factors, such as risk of disease-specific mortality, recurrence, benefit in initial staging, and follow-up, are weighted against the potential side effects of RAI.
Complications from RAI range from minor short-and long-term sialadenitis, nasolacrimal duct obstruction, and reproductive disturbances to more serious but rare forms of leukemia, myelosuppression, and aplastic anemia (6) (7) (8) (9) (10) . When controlling for other treatment exposures and taking into account dose-response effects, RAI appears to confer a modest increased risk of secondary hematologic malignancies, particularly at higher dose exposures, as evidenced in multiple cohorts worldwide (9) (10) (11) (12) (13) . These studies have grouped all hematologic malignancies under one broad category, but a recent analysis from the Surveillance, Epidemiology, and End Results registries suggests that RAI is associated with an increased early risk of acute myeloid leukemia (AML) and chronic myeloid leukemia but not of leukemias of lymphoid origin or of multiple myeloma (14) .
Clonal hematopoiesis (CH) refers to recurrent somatic mutations in leukemia-associated genes that are commonly acquired in aging human hematopoietic stem cells. Large-scale studies of asymptomatic individuals without known hematologic disease have identified somatic mutations in DNMT3, TET2, and ASXL1 that promote clonal expansion of progenitor cells in the absence of overt hematologic transformation (15) (16) (17) (18) , and these mutations persist over time. Healthy individuals with CH have been shown subsequently to develop hematologic cancers at a rate of ;0.5% to 1.0% per year compared with ,0.1% in non-CH controls, and CH has been linked to decreased overall survival (OS) (15, 16) . Hence, CH is a precursor clonal state that confers increased risk of developing leukemia.
The prevalence of CH has been recently found to be 25% among patients with cancer, with 4.5% of these harboring presumptive leukemia driver mutations at higher clonal burden [CH-potential driver (CH-PD)] (19) . The most common solid tumor associated with CH was thyroid carcinoma, with a prevalence of 36% (19) . CH was associated with increased age, prior radiation therapy, and tobacco use. CH and CH-PD led to an increased incidence of subsequent hematologic malignancies, and CH-PD was associated with shorter patient survival (19) . We designed the current study to explore why CH was enriched in patients with thyroid cancer. We hypothesized that the higher prevalence of CH among patients with thyroid cancer compared with other solid malignancies may be explained by the exposure of patients with thyroid cancer to RAI. If confirmed, CH may be a surrogate marker to validate the epidemiologic association seen between RAI and hematologic malignancies.
Methods

Human subjects
The study population included patients with thyroid carcinoma and no other concomitant hematologic malignancy treated at Memorial Sloan-Kettering Cancer Center (MSKCC) who underwent matched tumor and blood sequencing using the Memorial Sloan-Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) cancer panel (20) on an institutional prospective tumor sequencing protocol (ClinicalTrials.gov NCT01775072). This study was approved by the MSKCC Institutional Review Board. Patients with thyroid carcinoma undergoing MSK-IMPACT testing typically harbored recurrent or metastatic disease and were considered potentially to benefit from targeted therapies in the near future. Associations with any systemic cancer treatments or radiation therapy received before genotyping were ascertained by review of electronic medical records. Patients were excluded from analysis if they had an active hematologic cancer or precursor condition, such as monoclonal gammopathy of uncertain significance or monoclonal B cell lymphocytosis at the time of blood sequencing. Clinical characteristics were analyzed in all patients with thyroid cancer for whom MSK-IMPACT testing was performed between 16 May 2014 and 20 July 2017 (n = 309). Patients were prospectively followed for development of hematologic cancers and for OS through 31 January 2018.
Next-generation sequencing assay
All patients underwent next-generation sequencing using MSK-IMPACT, a hybridization capture-based next-generation sequencing assay encompassing all protein-coding exons of 468 cancer-associated genes (20) . MSK-IMPACT is validated and approved for clinical use by the New York State Department of Health Clinical Laboratory Evaluation Program and authorized by the Food and Drug Administration and is used to sequence patients with advance-stage cancer at MSKCC. DNA is extracted from deparaffinized formalin-fixed paraffin-embedded tumor tissue and patient-matched blood sample using the chemagic STAR instrument (Hamilton) with magnetic beads (PerkinElmer). Extracted DNA samples were normalized in Tris-EDTA buffer and sheared on the Covaris instrument. KAPA Biosystems library preparation kit was used to prepare barcoded DNA molecules on the Biomek FXP instrument. Libraries were pooled, and DNA fragments were captured using custom-designed biotinylated probes (NimbleGen). Further details have been previously described (20, 21) .
Determination of CH events
We identified CH mutations in all genes captured in MSK-IMPACT through a two-tiered filtering schema, where the variant allele fraction (VAF) in the blood was greater than twice the VAF in the tumor after removing false positives and germline mutations. The following criteria were used to retain mutations:
• Mutations present in nonleukemia/lymphoma genes where VAF is $5%, and at least eight reads supported the alternate allele.
• In samples where one CH mutation was identified, we also looked for the presence of additional mutations at lower variant frequencies, where mutations with VAF $1% in leukemia/lymphoma genes and VAF $3% for nonleukemia/ lymphoma genes were retained.
• For mutations in leukemia/lymphoma genes where the variant frequency was .35% in the blood sample but ,35% in the tumor tissue, which could conceivably be considered as germline events with loss of allele in tumor tissue, we included only the mutations that were present in the Catalogue for Somatic Mutations in Cancer (COSMIC) database with .10 occurrences in the ''hematopoietic and lymphoid'' category into the pool of CH mutations.
Determination of CH-PD events
Variants were considered for CH-PD if they had a VAF $10% in the blood sample and satisfied at least one of the following criteria: • Any inactivating mutation in CALR exon 9 
Survival determination
Survival data were obtained through internal MSKCC databases based on deaths while admitted to an MSKCC hospital or by Death Notification forms submitted from physicians' offices. Last known follow-up information was also electronically updated for all patients with activity at any MSKCC site. Additionally, vital status was updated electronically by using the Social Security Death Index matched against the MSKCC patient database. The Social Security Death Index update is run on a monthly basis. If there is no update or activity on a patient's account over a 15-month period, then the Omnipro Medicare Database is queried to determine vital status and/or data of last account activity.
Statistical analysis x
2 Tests, Student t tests, and Wilcoxon-rank sum tests were used to compare patient-and clinical-care characteristics among patients with and without CH. Logistic regression analysis was used to build multivariate models to examine the association between RAI and CH. The incidence of hematologic cancer, defined as the time from matched normal blood sampling to pathologically confirmed hematologic cancer development, was visually displayed using cumulative-incidence functions, whereas death in the absence of a hematologic malignancy was considered a competing event. OS, defined as the time from sample collection to death or last follow-up, was displayed using Kaplan-Meier curves. Cox-proportional hazards models were used to examine the association between CH and CH-PD and death. All statistical analyses were performed using STATA Statistical Software v12 (StataCorp).
Results
A total of 309 patients with thyroid carcinoma underwent MSK-IMPACT testing between 16 May 2014 and 20 July 2017. The overall prevalence of CH was 37% (115/309 patients) and that of CH-PD was 5.2% (16/309). Table 1 shows the prevalence of CH and CH-PD according to histologic subtype. There was no statistically significant difference in CH or CH-PD among the different subtypes of thyroid carcinoma. Ten percent of our patients (n = 30) had medullary thyroid carcinoma. Because patients with medullary thyroid carcinoma do not receive RAI as part of their treatment, they were excluded from our subsequent analyses. Out of 47 patients with anaplastic thyroid carcinoma, 10 (21.3%) had received RAI. The proportion of patients with anaplastic thyroid carcinoma who developed CH or CH-PD was comparable with the overall cohort, and therefore, they were included in our analyses. A total of 279 patients with follicular cell-derived thyroid carcinoma were analyzed. The median age of our population was 64 years (median, interquartile range = 64, 57 to 71). Older age was significantly associated with the presence of CH and CH-PD (Table 2) . CH occurred more often in black patients and less often in Asians (P = 0.023). We did not find a statistically significant association between smoking status and CH (P = 0.916). Seventy-five percent of our population was treated with RAI. A higher administered dose of RAI was significantly associated with CH and CH-PD. The median time from exposure to RAI to testing for CH or CH-PD was 1349 days (minimum 19 days; maximum 12,691 days). Other therapies, including external beam radiation therapy (EBRT) and chemotherapy, were not significantly associated with CH or with CH-PD ( Table 2) .
To explore further the association between administered dose of RAI and CH or CH-PD, we built multivariate logistic regression models (Table 3) . We found that age and dose of RAI were significantly associated with CH and CH-PD when adjusted for EBRT and chemotherapy. Specifically, for every year increase in age, there was a 5% increase in the odds of having CH and a 13% increase in the odds of having CH-PD when adjusted for RAI administration, EBRT, and chemotherapy. RAI was also independently associated with CH and CH-PD. For every 10 mCi increase of RAI administered, there was a 2% increase in the odds of having CH and a 4% increase in the odds of having CH-PD when adjusted for age, EBRT, and chemotherapy. There was no significant association between EBRT or chemotherapy and CH or CH-PD (Table 3) .
We next sought to identify any potential associations among RAI, CH, and leukemia. We only had one CHpositive case of myelodysplastic syndrome, one CHnegative case of myelofibrosis, and two of monoclonal gammopathy of uncertain significance in the follow-up period (one CH positive; one CH negative). We found higher median doses of RAI administered to patients who subsequently developed these hematologic disorders compared with those who did not (316 vs 151 mCi), but this association was not statistically significant (P = 0.27). This may be, in part, a result of the short follow-up period of our cohort.
We assessed whether the presence of CH had an effect on OS. With the consideration of the entire population, we did not find a statistically significant association between CH and OS [heart rate (HR) = 1.3, 95% CI = 0.76 to 2.32, P = 0.319]. However, among patients who had been exposed to any dose of RAI, CH conferred a borderline, significantly poorer survival (HR = 2.16, 95% CI = 0.95 to 4.94, P = 0.06). This weak association did not persist after stratifying by age (P = 0.11). CH-PD had a borderline-significant association with decreased OS in the overall cohort (HR = 2.4, 95% CI = 0.96 to 6.2, P = 0.06), but when considered only for patients exposed to RAI, CH-PD had a strong association with adverse survival (HR = 4.1, 95% CI = 1.4 to 12.1, P = 0.01), which persisted after stratifying by age (HR = 3.75, 95% CI = 1.23 to 11.5, P = 0.02). Figure 1 shows KaplanMeier survival estimates of patients exposed to RAI with and without CH-PD. Figure 1A shows the entire cohort of patients, and Fig. 1B shows patients with differentiated thyroid carcinoma, excluding those with anaplastic thyroid cancer.
Discussion
In this study, we found that the prevalence of CH in patients with thyroid cancer was 37%, and that of potential drivers of hematologic malignancies (CH-PD) was 5.2%. Age was the strongest predictor of CH and CH-PD. For every year increase in age, there was a 5% and 13% increase in the odds of CH and CH-PD, respectively. Dose of RAI was significantly associated with CH and CH-PD, even after adjustment for age, EBRT, and chemotherapy. For every 10 mCi increase in the dose of RAI administered, there was a 2% and 4% increase in the odds of CH and CH-PD, respectively. Among patients who had received RAI, those with CH-PD had a significantly shorter OS, even when stratified by age. With a rising incidence of thyroid carcinoma and the consequent large pool of long-term survivors who received RAI therapy, there is an understandable concern about the risk of secondary malignancies in general and hematologic malignancies in particular. Previous studies described the association between RAI and hematologic malignancies (9, 14, (23) (24) (25) . This report demonstrates a dose-dependent association between RAI and clonal events that have a low probability of leading to the development of hematologic malignancies.
Ionizing radiation induces chromosomal aberrations frequently found in secondary leukemias, and its causal contribution to leukemogenesis has generally been established (26) . Nevertheless, the link between RAI and the evolution to leukemia has long been a matter of debate, as early epidemiological studies yielded conflicting results (27) (28) (29) . In a comprehensive review and meta-analysis of the literature covering 16,502 patients with thyroid cancer, the relative risk for the development of leukemia increased 2.5-fold in patients treated with radioiodine (30) . In line with this, thyroid cancer was also identified as the secondmost common primary neoplasm arising in patients who developed AML following treatment of solid cancers (31) and as the most common primary malignancy associated with CH (19) . Based on current evidence, CH is a precursor clonal state conferring a five-to 10-fold greater risk for development of hematological neoplasms compared with non-CH controls (15, 16, 32, 33) . Therefore, the signal for association of CH with RAI exposure in our retrospective series justifies the development of a more rigorously designed study to ascertain dose response, time course, persistence of CH, and longitudinal risk for development of hematologic malignancies to confirm this association.
Besides assessing for risk, there is intriguing preclinical evidence suggesting that patients with CH harboring mutations of TET2 may benefit from treatment with vitamin C. Loss-of-function heterozygous mutations in TET2 occur frequently in patients with CH, myelodysplastic syndrome, and AML and are associated with DNA hypermethylation. Treatment with vitamin C, a cofactor of Fe2 + and a-ketoglutarate-dependent dioxygenases, can reverse the hypermethylation state by enhancing 5-hydroxymethylcytosine formation. In mouse models, this has been shown to suppress human leukemic colony formation and leukemia progression (34, 35) . CH and particularly CH-PD were associated with poorer survival. In contrast to CH, in a general population without a diagnosis of advanced cancer, where the primary cause of death is attributed to cardiovascular events, the main reason for this cohort's demise was progression of its primary thyroid carcinoma. The association between CH and cancer progression could be a result of cell-cell interactions among mutant myeloid clones and cancer cells (36) , impact of CH on immune surveillance, or other factors that will require further clinical and functional investigation.
The findings of our study are limited by the fact that our cohort was composed of thyroid cancer patients with advanced disease stage and older age. The high prevalence of CH may be related to the increased age of our population compared with that of subjects with other solid tumors. In addition, the low incidence of hematologic malignancies prevented us from exploring the association among RAI, CH, and leukemia, which may have been a result of the short follow-up time after sequencing of their blood, compounded by the fact that mortality was high in this population with advanced thyroid cancer. Furthermore, the association between CH-PD and decreased survival among patients exposed to RAI may be related to the advanced stage of the tumors genotyped. It remains unclear if the association of CH with poor prognosis would also be seen in younger patients with more indolent disease.
In conclusion, the model that has been proposed (19) and further validated here is that age-dependent mutations are constantly acquired in hematopoietic stem cells, which are then selected for by external perturbations, such as RAI, which allow clones to expand. These mutant hematopoietic clones may impact the biology and therapeutic response of primary tumors, besides conferring an increased risk of hematologic malignancies. RAI is associated with a high prevalence of CH, and CH is a precursor state of hematologic malignancies. The extent to which the presence of CH should be considered before administration of RAI is unclear. Furthermore, identification of CH and particularly of CH-PD may inform lifestyle interventions and the use of molecularly targeted therapies to prevent clonal expansion and subsequent hematologic malignancies.
